Susan Foster will be a panelist in the case study session, "Oxford BioTherapeutics – Menarini deal," at Genesis 2012 which is hosted by One Nucleus and SCRIP Intelligence. Mintz Levin is a proud sponsor of Genesis 2012.
Each case study session will focus on one deal in the biopharma space, discussing some of the challenges and solutions relating to matters such as the deal's genesis, challenges in the negotiation or management of the resulting alliance. The discussion will be aided by a panel of biopharma experts who will lead on aspects of the questioning with a view to providing delegates with an insight into the actual or possible solutions implemented and their impact.
- Christian Rholff, CEO, Oxford BioTherapeutics
- Andrew Slade, President, Menarini Biotech
- Susan Foster, Mintz Levin
- Sam Williams, CEO, Conformetrix
- Neill Moray Mackenzie, Roji Ltd